[Evidence summary]: Is there evidence of mRNA vaccine effectiveness with an extended dosing interval? If so, what is the interval? [V1.0]
dc.contributor.author | Leen, Brendan | |
dc.contributor.author | White, Gethin | |
dc.contributor.author | Carrigan, Marie | |
dc.contributor.author | O'Reilly, Peter | |
dc.contributor.author | Bambury, Niamh | |
dc.contributor.author | Casey, Geraldine | |
dc.contributor.author | Beatty, Kenneth | |
dc.contributor.author | Mullane, Paul | |
dc.contributor.author | White, Philippa | |
dc.date.accessioned | 2021-08-20T15:37:45Z | |
dc.date.available | 2021-08-20T15:37:45Z | |
dc.date.issued | 2021-08 | |
dc.identifier.uri | http://hdl.handle.net/10147/630148 | |
dc.description | Main Points 1. The WHO and CDC recommend that in exceptional epidemiological circumstances, countries may consider extending the dosing interval to a maximum of 42 days . Currently, only limited data are available on the efficacy of mRNA COVID 19 vaccines administered beyond the 42 day window. 2. Modelling studies suggest that initially vaccinating a greater number of people with a single dose will prevent more deaths and hospitalizations than vaccinating a smaller number of people w ith 2 doses ; and that extending the dosing interval shows progressive benefit to population immunity 3. Data suggest that the second dose should not be delayed in t hose >65 years of age or in immunosuppressed individuals such as cancer patients or transplant recipients due to reduced vaccine immunogenicity after the first dose. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Health Service Executive | en_US |
dc.relation.ispartofseries | Q.207 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | VACCINATION | en_US |
dc.subject | IMMUNISATION | en_US |
dc.title | [Evidence summary]: Is there evidence of mRNA vaccine effectiveness with an extended dosing interval? If so, what is the interval? [V1.0] | en_US |
dc.type | Other | en_US |
refterms.dateFOA | 2021-08-20T15:37:46Z |
Files in this item
This item appears in the following Collection(s)
-
HSE Library Summaries of Evidence
Evidence summaries and reviews on the management and treatment of Novel Coronavirus Covid-19 and other clinical topics